NCT05687058View on ClinicalTrials.gov

Empagliflozin in ESKD - A Feasibility Study

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

October 30, 2025

Study Completion Date

December 31, 2025

Conditions
Kidney Failure, ChronicHeart Failure
Interventions
DRUG

Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing

Participants in Group I will be asked to take empagliflozin 25 mg after each hemodialysis session at home.

DRUG

Empagliflozin 10 mg daily dosing

Participants assigned to Group II will be asked to take empagliflozin 10 mg each morning between 8:30 and 9:30 a.m. at home.

Trial Locations (2)

39157

RECRUITING

University of Mississippi Medical Center, Jackson

39213

RECRUITING

Jackson Medicall Mall Dialysis Clinic, Jackson

All Listed Sponsors
lead

University of Mississippi Medical Center

OTHER